Humanized antibodies to iNKT
US9932402B2 · kind B2 · utility
2Cited by
7References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 26, 2012 |
| Grant date | Apr 3, 2018 |
| Priority date | — |
| Expiry date | Oct 26, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of treatment to suppress an immune response are provided. The method comprises administering to a subject in need of treatment a naked blocking antibody that binds selectively iNKT cells in an amount effective to suppress the subject's iNKT cell function. Compositions comprising, an isolated, humanized antibody that binds selectively iNKT cells are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.